Christopher Ritchlin, MD
Rheumatology · Rochester, NYNPI 1497775472
Payments from drug & device makers
Across 582 payments — averaging $2982.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$677K
- UCB SA$200K
- E.r. Squibb & Sons, L.L.C.$165K
- Janssen Research & Development, LLC$141K
- AbbVie$126K
- Amgen$113K
- plus $314K from 18 others
Across 19 payments — averaging $1766.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$16K
- Pfizer$12K
- Novartis$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 116 | $676,826 |
| UCB SA | 27 | $200,408 |
| E.r. Squibb & Sons, L.L.C. | 49 | $164,670 |
| Janssen Research & Development, LLC | 14 | $141,151 |
| AbbVie | 73 | $126,013 |
| Amgen | 6 | $112,597 |
| UCB, Inc. | 13 | $100,113 |
| Pfizer | 67 | $72,789 |
| Janssen Scientific Affairs, LLC | 130 | $48,199 |
| Mindera Corp | 2 | $28,646 |
| Janssen Global Services, LLC | 9 | $16,200 |
| Lilly USA, LLC | 7 | $12,120 |
| Eli Lilly | 5 | $12,019 |
| Johnson & Johnson | 7 | $6,753 |
| Sanofi US Services Inc. | 3 | $5,382 |
| Whitehall International Inc | 1 | $3,669 |
| Gilead | 2 | $2,794 |
| Sanofi | 18 | $2,773 |
| Genentech USA, Inc. | 8 | $1,091 |
| Genentech, Inc. | 19 | $840 |
| Assertio Therapeutics, Inc. | 2 | $475 |
| Novartis Pharma AG | 2 | $352 |
| Sun Pharmaceutical Industries Inc. | 1 | $82 |
| Merck | 1 | $61 |
How this compares
$1,736,022 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Rochester
- Ignacio SanzRochester$1.4M
- Ugo AwaRochester$435K
- Jennifer AnolikRochester$408K
- Allen AnandarajahRochester$404K
- Benjamin KormanRochester$327K
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.